Let me reframe this question before we look at charts and cutoffs.

When patients ask me "Am I eligible for GLP-1 medication?", they are usually asking whether they meet a clinical threshold on paper. That is a reasonable starting point. But the more important question is: Is excess body fat currently damaging your brain? Because if the answer is yes — and for a large percentage of men, it is — then getting metabolically lean is not optional. It is a cognitive longevity imperative.

Visceral fat is metabolically active tissue. It produces inflammatory cytokines — IL-6, TNF-alpha, C-reactive protein — that circulate systemically and cross the blood-brain barrier. Once inside, they trigger neuroinflammation, disrupt hippocampal neurogenesis, and accelerate the same pathological cascades associated with cognitive decline. We are not talking about vague future risk. For many men carrying significant visceral load, the process has already started.

GLP-1 medication is one of the most powerful tools we have to reverse that trajectory. It reduces visceral fat aggressively, improves insulin sensitivity, lowers systemic inflammation, and — according to emerging research — may have direct neuroprotective effects. But it is a tool within a protocol, not a standalone fix. The 4M framework — Mind, Muscle, Mitigate, Motivate — is the protocol that makes the results stick.

BMI Requirements and Clinical Criteria

FDA labeling and clinical guidelines establish the following eligibility thresholds for GLP-1 medications:

  • BMI of 30 or higher (obesity): You are generally eligible. A BMI of 30 represents roughly 30 or more pounds over a metabolically healthy weight for most adults. This is also the threshold at which visceral fat accumulation becomes clinically significant and neuroinflammatory risk rises sharply.
  • BMI of 27–29.9 (overweight) with a weight-related condition: You may qualify if you also carry at least one comorbidity — type 2 diabetes, elevated blood pressure, dyslipidemia, obstructive sleep apnea, or established cardiovascular disease. Many men in this BMI range have significant visceral fat despite appearing "borderline" on a standard scale.

You can calculate your BMI at our free BMI calculator, or we will do it during your consult. BMI is a crude proxy — it does not distinguish visceral from subcutaneous fat — but it is the standard clinical entry point, and it is where we start.

Conditions That Strengthen Your Case

Beyond weight alone, GLP-1 therapy has demonstrated meaningful clinical benefit across a range of obesity-related conditions. If you carry any of the following, your case for treatment is stronger — and the urgency is higher:

  • Type 2 diabetes or prediabetes: Both semaglutide and tirzepatide are FDA-approved for type 2 diabetes management. Restoring insulin sensitivity directly reduces the neuroinflammatory burden that drives cognitive decline.
  • Hypertension: Visceral fat drives hypertension through multiple pathways. Weight reduction from GLP-1 therapy produces clinically meaningful blood pressure improvements in most patients.
  • Dyslipidemia: Elevated triglycerides and low HDL — the metabolic syndrome signature — are common in men carrying visceral fat. GLP-1 therapy consistently improves lipid profiles.
  • Obstructive sleep apnea: Poor sleep is one of the primary drivers of cognitive decline in middle age. Weight reduction significantly improves or resolves sleep apnea in most patients.
  • Cardiovascular disease or elevated risk: The SELECT trial demonstrated that semaglutide reduces major cardiovascular events. A healthy cardiovascular system is the brain's delivery infrastructure.

Who Should NOT Take GLP-1 Medications

GLP-1 therapy is not appropriate for everyone. Contraindications include:

Important Contraindications:
  • Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2: GLP-1 receptor agonists carry an FDA boxed warning based on rodent carcinogenicity studies. This is a hard contraindication.
  • Active or history of severe pancreatitis: GLP-1 medications have been associated with rare pancreatitis events. A history of recurrent or severe pancreatitis requires careful evaluation.
  • Pregnancy or planned pregnancy: These medications are not approved during pregnancy and should be discontinued at least two months before attempting conception.
  • Severe gastrointestinal disease: Gastroparesis and severe inflammatory bowel disease are relative contraindications due to GLP-1's effect on gastric motility.
  • Type 1 diabetes: GLP-1 weight loss protocols are not indicated for type 1 diabetes management.

Your contracted licensed telemedicine provider — part of the My4MLife program — will conduct a thorough medication review as part of your comprehensive consult. Certain drugs, particularly insulin and sulfonylureas, require dose adjustment when GLP-1 therapy is initiated.

What the Comprehensive 4M Consult Covers

This is not a telehealth click-through. The comprehensive 4M consult is a structured intake that covers your full metabolic and cognitive health picture:

  1. Personalized Assessment review: Before your consult, you complete the free Personalized Assessment at /assessment. This gives the clinician a baseline on your metabolic health, sleep quality, stress load, hormonal history, and cognitive function. The consult starts from data, not from scratch.
  2. Full medical history and medication review: A contracted licensed telemedicine provider reviews your health history, lab work (or orders labs if needed), and current medications to confirm eligibility and rule out contraindications.
  3. Protocol design: If GLP-1 medication is appropriate, your prescriber recommends the specific agent (semaglutide vs. tirzepatide — more on this in the next post), starting dose, and titration schedule. This is paired with your Month 1 4M Cohort protocol — gut repair, sleep optimization, hormone foundation, cognitive baseline — because the medication and the protocol work together.
  4. Prescription and fulfillment: If approved, your prescription is sent to a licensed compounding pharmacy. Medication ships to your door.
  5. Ongoing check-ins: Regular follow-up ensures titration is progressing well and allows for adjustment based on your response.

Common Questions About Eligibility

I have tried diet and exercise and failed. Does that disqualify me? The opposite. GLP-1 medications exist precisely for patients who have struggled with conventional approaches. Prior failed attempts often strengthen the clinical case for medical intervention.

What if my BMI is borderline — say, 28 or 29? Your prescriber will evaluate the full picture: waist circumference, metabolic markers, body composition, and comorbidities. Some patients with borderline BMI have significant visceral fat and strong clinical indications for treatment. The consult is where that gets sorted out.

Is there an age limit? GLP-1 medications are indicated for adults 18 and older. The 4M program is specifically designed for men — the decade where visceral fat accumulation accelerates and cognitive risk begins to compound.

What about cost? Compounded versions of semaglutide and tirzepatide are available at significantly lower cost than brand-name alternatives. Your prescriber can walk through pricing during the consult.

Key Takeaway: The goal is not to lose weight so you look better. The goal is to restore metabolic health so your brain has decades more of high-quality function. GLP-1 medication is a powerful clinical lever in that mission. The 4M framework is what makes it stick. Start with the free Personalized Assessment — then book your comprehensive consult.